Efficacy of Wet Cupping in Hypertension

Efficacy of Hijama bish Shart (Wet Cupping) in Dyslipidemic Hypertension - A Randomized Controlled Clinical Trial - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/07/069734

Enrollment

Registered

2024-07-01

Start date

Unknown

Completion date

Unknown

Last updated

2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I158- Other secondary hypertension

Interventions

Intervention1: Hijama bish Shart (Wet Cupping) with lifestyle modifications: Subjects in group A will undergo for 4 sittings of Hij ?ma bish Shar? at a regular interval of 7 days upto 30 days along wi

Eligibility

Inclusion criteria

Inclusion criteria: 1 Clinically newly diagnosed patients of high blood pressure having Systolic Blood Pressure less than 160 mmHg and or diastolic blood pressure less than 100mmHg 2 Patients with abnormal lipid profile (Total cholesterol or triglycerides more than 250 mg/dl) 3 Patients between 20-65 years of age 4 Patients of either gender 5 Patients who are willing and able to sign the informed consent form

Exclusion criteria

Exclusion criteria: Patients having grade III hypertension (SBP more than or equal to 160 mmHg and /or DBP more than or equal to 100 mmHg) 2 Pregnant and lactating women 3 patients who had undergone wet cupping within the previous 6 months. 4 patients who required anti-hypertensive medication dose or type changes during the follow-up period. 5 Patients of diabetes mellitus (RBS greater than 250 mg/dl) 6 patients having any CVD or CKD of any stage. 7 patients with any localized skin lesion on the upper back (where the integrity of the skin is compromised). 8 patients who donated blood within the previous month. 9 Patients of Anemia (Hb is less than 12 mg/dl in Male and less than 10 mg/dl in Female patients.) 10 patients have bleeding diathesis, HIV infection, and hepatitis B & C infection.

Design outcomes

Primary

Measure	Time frame
1 Improvement in Blood Pressures, both Systolic and Diastolic Improvement in Lipid Profile (Total cholesterol, Triglycerides, LDL Cholesterol and HDL Cholesterol) Timepoint: at baseline and after treatment	—

Secondary

Measure	Time frame
NILTimepoint: NIL	—

Countries

India

Contacts

Public ContactDr Mohd Nayab

National Institute of Unani Medicine

nayabdr@gmail.com9019080556

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026